StockData
AbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL) shareholders

ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30172% above fair value
$11.03−0.09 (-0.81%)

Close on Nov 17, 2026Market cap $3.38BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
37.9%
116M of 307M shares
Institutional holders
151
39 new, 26 sold out
Net institutional buying
-8M
In Q2 2026
Insider trades, 12 months
11 buys · 0 sales
Net bought $3.47M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Carl L.G. Hansen
Joint filing with Thermopylae Holdings Ltd. (19.20%)
60,740,52420.60%13G (passive) amendmentDec 31, 2023
Baker Bros. Advisors LP
Joint filing with Baker Bros. Advisors (GP) LLC (10.80%), Julian C. Baker (10.80%) and 1 more
33,012,13810.80%13G (passive) amendmentApr 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ABCLValueChange% of portfolio
Baker Bros. Advisors LP33,012,13810.77%$259.15M+2,736,2001.30%
Capital World Investors13,588,3494.43%$106.67M+227,2530.01%
Two Sigma Investments, LP10,437,4313.40%$81.93M−124,6340.06%
TD Waterhouse Canada Inc.9,568,1493.12%$72.62M+3,4900.19%
Bank Of America Corp /De/6,141,5392.00%$48.21M+3,141,6030.00%
UBS Asset Management Americas Inc4,317,2061.41%$33.89M−3,258,2700.01%
ArrowMark Colorado Holdings LLC4,105,0951.34%$32.22M–1.34%
BlackRock, Inc.3,805,3091.24%$29.87M−234,9270.00%
Driehaus Capital Management LLC2,864,7290.93%$22.49M−1,160,0500.13%
Tudor Investment Corp Et Al2,063,1910.67%$16.20M−210,2980.02%
Marshall Wace, Llp1,902,1910.62%$14.93M+1,542,5080.01%
UBS Group AG1,870,6330.61%$14.68M−2,338,4190.00%
Morgan Stanley1,669,0140.54%$13.10M−555,8150.00%
Price T Rowe Associates Inc /Md/1,587,8700.52%$12.47MNew0.00%
Citadel Advisors LLC1,586,5120.52%$12.45M+225,4070.00%
National Bank Of Canada /Fi/1,233,0140.40%$9.68M+1,231,6210.01%
Arrowstreet Capital, Limited Partnership1,039,9270.34%$8.16MNew0.00%
Renaissance Technologies LLC990,9290.32%$7.78M−519,7000.01%
Counterpoint Mutual Funds LLC971,6430.32%$7.63MNew0.75%
State Street Corp731,3620.24%$5.74M+1,1490.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026151116M37.9%39 / 3654 / 2617M25M
Q1 2026138124M40.5%20 / 5335 / 2629M13M
Q4 2025144109M35.4%31 / 5038 / 2824M19M
Q3 2025142104M34.0%35 / 4435 / 2115M19M
Q2 2025128108M35.3%19 / 3843 / 1810M37M
Q1 2025129136M44.4%12 / 3351 / 2734M11M
Q4 2024146114M37.2%27 / 4539 / 1718M8M
Q3 2024139106M34.6%19 / 5234 / 2717M22M
Q2 2024148115M37.4%20 / 3748 / 2510M13M
Q1 2024154122M39.8%27 / 4741 / 159M7M
Q4 2023143120M39.1%26 / 4835 / 198M8M
Q3 2023138120M39.1%19 / 3839 / 517M12M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

25 funds held ABCL in Q2 2026, 20% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ABCLValue% of fundAs of
SMALLCAP World Fund Inc13,228,5964.31%$103.84M0.11%Jun 30, 2026
iShares Biotechnology ETF1,656,2040.54%$13.00M0.14%Jun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1,053,9000.34%$8.27M0.06%Jun 30, 2026
Counterpoint Quantitative Equity ETF971,6430.32%$7.63M2.07%Jun 30, 2026
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF564,3200.18%$4.43M0.01%Jun 30, 2026
iShares Genomics Immunology and Healthcare ETF508,9350.17%$2.91M1.52%Jul 31, 2026
SMALLCAP World Fund359,7530.12%$2.82M0.11%Jun 30, 2026
BlackRock Advantage Small Cap Core Fund339,6220.11%$2.10M0.04%May 29, 2026
Driehaus Micro Cap Growth Fund246,5600.08%$1.94M0.32%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund180,1330.06%$1.11M0.00%May 31, 2026
State Street(R) SPDR(R) S&P(R) International Small Cap ETF166,0420.05%$1.30M0.15%Jun 30, 2026
Fidelity Nasdaq Composite Index ETF134,6740.04%$830.94K0.01%May 31, 2026
Small Cap Value Fund123,7120.04%$971.14K0.14%Jun 30, 2026
Adara Smaller Companies Fund120,1620.04%$741.40K0.09%May 31, 2026
Avantis U.S. Equity ETF64,8110.02%$399.88K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Carl L. G. HansenChief Executive Officer, Director, 10% owner56,984,00918.59%Jan 5, 2026
Veronique LecaultChief Technology Officer, Director9,340,0443.05%Jan 5, 2026
Andrew BoothChief Financial Officer622,3590.20%Nov 16, 2026
Tryn StimartChief Legal Officer5000.00%Jan 5, 2026
Michael R. HaydenDirector1,491,6420.49%Aug 24, 2026
John S. MontalbanoDirector256,0000.08%Aug 18, 2026
Victor SandorDirector––Jul 6, 2026
Lynn SeelyDirector––Jul 6, 2026
Stephen QuakeDirector1,100,4360.36%Jun 12, 2026
Andrew LoDirector86,9380.03%Jun 16, 2025
Holdings Ltd. Thermopylae10% owner56,069,66218.29%Nov 13, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Andrew Booth
Chief Financial Officer
Nov 13, 2026Gift−50,000––491,400
Andrew Booth
Chief Financial Officer
Nov 13, 2026Option exercise+50,000$0.32$16.08K541,400
Holdings Ltd. Thermopylae
10% owner
Nov 13, 2026Gift−125,000––56,069,662
Andrew Booth
Chief Financial Officer
Nov 13, 2026Buy+8,600$11.33$97.44K491,400
Holdings Ltd. Thermopylae
10% owner
Nov 12, 2026Buy+60,565$11.54$698.92K56,194,662
Michael R. Hayden
Director
Aug 24, 2026Buy+53,613$10.64$570.44K1,373,397
John S. Montalbano
Director
Aug 18, 2026Buy+10,000$11.03$110.30K251,000
Andrew Booth
Chief Financial Officer
Aug 14, 2026Buy+37,200$10.32$383.90K482,800
Michael R. Hayden
Director
Aug 12, 2026Buy+46,387$10.37$481.03K1,319,784
Michael R. Hayden
Director
Aug 11, 2026Gift−50,000––1,273,397
Andrew Booth
Chief Financial Officer
Jun 3, 2026Option exercise+250,000$0.19$47.50K445,600
John S. Montalbano
Director
May 14, 2026Buy+20,000$4.77$95.40K241,000
Holdings Ltd. Thermopylae
10% owner
Feb 27, 2026Buy+38,000$3.44$130.72K56,134,097
Andrew Booth
Chief Financial Officer
Feb 27, 2026Buy+42,600$3.42$145.69K195,600
Holdings Ltd. Thermopylae
10% owner
Feb 26, 2026Buy+177,457$3.27$580.28K56,096,097
Holdings Ltd. Thermopylae
10% owner
Dec 18, 2025Gift−225,000––55,918,640
John S. Montalbano
Director
Nov 26, 2025Buy+50,000$3.57$178.50K221,000
Holdings Ltd. Thermopylae
10% owner
Mar 11, 2025Buy+343,631$2.16$742.24K56,143,640
John S. Montalbano
Director
Mar 10, 2025Buy+25,000$2.30$57.50K171,000
John S. Montalbano
Director
Mar 6, 2025Buy+60,000$2.34$140.40K146,000
Holdings Ltd. Thermopylae
10% owner
Dec 4, 2024Gift−286,000––55,800,009
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Nov 25, 2024Option exercise+56,125$2.70$151.54K898,000
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Sep 20, 2024Option exercise+56,125$2.70$151.54K841,875
Holdings Ltd. Thermopylae
10% owner
Aug 29, 2024Buy+283,516$2.61$739.98K56,086,009
Veronique Lecault
Chief Operating Officer, Director
Jun 21, 2024Option exercise+83,334$0.19$15.83K2,123,456
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
May 31, 2024Option exercise+56,125$2.70$151.54K785,750
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Feb 26, 2024Option exercise+56,125$2.70$151.54K729,625
Holdings Ltd. Thermopylae
10% owner
Dec 19, 2023Gift−210,000––55,802,493
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Nov 23, 2023Option exercise+56,125$2.70$151.54K673,500
John S. Montalbano
Director
Nov 8, 2023Buy+10,000$4.46$44.60K86,000
John S. Montalbano
Director
Nov 6, 2023Buy+20,000$4.64$92.80K76,000
Michael R. Hayden
Director
Sep 22, 2023Buy+20,000$4.91$98.20K1,323,397
Veronique Lecault
Chief Operating Officer, Director
Sep 12, 2023Buy+20,000$5.19$103.80K2,040,122
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Aug 24, 2023Option exercise+56,125$2.70$151.54K617,375
Michael R. Hayden
Director
Aug 8, 2023Buy+30,000$5.90$177.00K1,303,397
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
May 26, 2023Option exercise+56,125$2.70$151.54K561,250
Andrew Booth
Chief Financial Officer
May 26, 2023Buy+14,500$6.85$99.33K153,000
Holdings Ltd. Thermopylae
10% owner
May 26, 2023Buy+153,000$6.52$997.56K56,012,493
Veronique Lecault
Chief Operating Officer, Director
May 5, 2023Option exercise+250,000$0.19$47.50K2,020,122
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Feb 22, 2023Option exercise+56,125$2.70$151.54K505,125
Andrew Booth
Chief Financial Officer
Dec 20, 2022Option exercise+50,000$0.19$9.50K188,500
Andrew Booth
Chief Financial Officer
Dec 20, 2022Gift−50,000––138,500
Holdings Ltd. Thermopylae
10% owner
Dec 16, 2022Buy+85,102$10.10$859.53K55,859,493
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Nov 18, 2022Option exercise+56,125$2.70$151.54K449,000
Holdings Ltd. Thermopylae
10% owner
Oct 31, 2022Gift−70,000––55,774,391
Holdings Ltd. Thermopylae
10% owner
Aug 19, 2022Buy+200,000$11.46$2.29M55,844,391
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Aug 18, 2022Option exercise+56,125$2.70$151.54K392,875
Holdings Ltd. Thermopylae
10% owner
Jun 14, 2022Buy+9,173$8.05$73.84K55,644,391
Holdings Ltd. Thermopylae
10% owner
Jun 13, 2022Buy+54,915$8.03$440.97K55,635,218
Holdings Ltd. Thermopylae
10% owner
Jun 6, 2022Buy+64,545$7.50$484.09K55,580,303
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
May 18, 2022Option exercise+56,125$2.70$151.54K336,750
Veronique Lecault
Chief Operating Officer, Director
May 16, 2022Buy+200,000$6.34$1.27M1,770,122
Holdings Ltd. Thermopylae
10% owner
May 13, 2022Buy+300,000$7.26$2.18M55,515,758
Andrew Booth
Chief Financial Officer
May 12, 2022Buy+85,000$5.79$492.15K138,500
Holdings Ltd. Thermopylae
10% owner
May 12, 2022Buy+1,408,468$6.41$9.03M55,215,758
John S. Montalbano
Director
Mar 4, 2022Buy+10,000$8.54$85.40K56,000
John S. Montalbano
Director
Mar 1, 2022Buy+20,000$9.05$181.00K46,000
Veronique Lecault
Chief Operating Officer, Director
Feb 28, 2022Buy+230,789$8.66$2.00M1,570,122
Carl L. G. Hansen
Chief Executive Officer, Director, 10% owner
Feb 22, 2022Option exercise+56,125$2.70$151.54K280,625
Andrew Booth
Chief Financial Officer
Dec 10, 2021Gift−500,000––53,500

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.26%
29M shares short
Days to cover
8.5
At 3M shares a day
Change since last report
-6.2%
From 31M shares
Short volume, 20 days
43.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AbCellera Biologics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 82,773 shares on Aug 26, 2026 over the last 90 days.

See a number that looks wrong?